L-THEANINE AND MEDITERRANEAN DIET ON RBD, GI FUNCTION, AND INFLAMMATION IN PARKINSON'S DISEASE

NCT07682532 | Recruiting

• 1 other identifier: 125S555
• Study Type: interventional
• Target: 52
• Locations: 1 country
• Sites: 1

Brief Summary

Parkinson's disease is a progressive neurological disorder associated with severe dopaminergic neuron loss in the substantia nigra pars compacta. The decrease in dopamine cells in the gut in Parkinson's disease negatively affects bowel movements, and constipation is a common condition. Impairment of the intestinal barrier increases inflammation. Reactive oxygen species increase, and intestinal homeostasis changes. Alpha-synuclein levels increase in the gut. L-theanine is the most abundant amino acid in green tea leaves. Parkinson's patients exhibit increased oxidative stress along with decreased activity of glutathione peroxidase, superoxide dismutase, and catalase. L-theanine is believed to increase the activity of these enzymes and reduce oxidative stress. L-theanine administration has been found to increase total short-chain fatty acids in stool. Furthermore, it is suggested that L-theanine inhibits imbalances in oxidative stress and inflammatory responses by reducing inflammatory factors such as TNF-α, IL-6, and IL-1β. REM sleep disturbance is also a common problem in Parkinson's disease. Studies have shown that following L-theanine treatment, participants' Pittsburgh Sleep Quality Index (PSQI) scale scores improved. The gut microbiota regulates sleep and neurological states via the microbiota-gut-brain axis. L-theanine supplementation appears to be able to regulate gut bacterial composition to suppress neurotransmitters, cytokines, and other metabolites to regulate sleep. The protective effects of L-theanine administration on increased dopamine and other neurotransmitters, microbiota, sleep, and antioxidant enzymes may offer a glimmer of hope regarding its beneficial role in Parkinson's disease.

Conditions

Parkinson Disease (PD)

Keywords

Parkinson's disease; REM sleep behavior disorder; inflammation; nutrition

Outcome Measures

Primary Outcomes (1)

• RBD Screening Questionnaire (RBDSQ) score

  Change in RBD Screening Questionnaire (RBDSQ) score from baseline to week 4. RBDSQ is a 13-item self-reported questionnaire assessing REM sleep behavior disorder symptoms. Scores range from 0 to 13; higher scores indicate greater RBD severity.

  from baseline to week 4

Study Arms (2)

L-Theanine + Mediterranean Diet

EXPERIMENTAL

200 mg of L-theanine supplement will be given daily. A Mediterranean diet will be followed.

Dietary Supplement: Dietary Supplement

Placebo + Mediterranean Diet

PLACEBO COMPARATOR

200 mg of placebo corn starch will be given daily. A Mediterranean diet will be followed.

Other: Control group (placebo)

Interventions

Dietary Supplement DIETARY_SUPPLEMENT

L-theanine supplementation combined with Mediterranean diet for 4 weeks.

L-Theanine + Mediterranean Diet

Control group (placebo) OTHER

Placebo combined with Mediterranean diet for 4 weeks.

Placebo + Mediterranean Diet

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients diagnosed with Parkinson's Disease and classified as stage 1 according to the Hoehn-Yahr Staging (HYA), Patients without communication impairment (aphasia) Participants who sign the Informed Consent Form and volunteer to participate in the study Absence of dementia and Mini Mental State Examination (MMSE) score \> 24 Living in the same household with a healthy spouse/partner Not taking prebiotic, fiber, probiotic, herbal, or high-dose vitamin or mineral supplements that may affect inflammation during the pre-onset period and throughout the study protocol

You may not qualify if:

• Patients with a history of severe heart, lung, liver, or kidney failure, primary psychiatric, developmental, or other neurological disease Patients using sedative/hypnotic medications Individuals consuming more than 200 mg of caffeine per day (approximately 2-3 cups of tea or 1 cup of coffee) Patients who smoke and consume alcohol Having undergone surgery related to bowel health Having a chronic infectious bowel disease Having a congenital bowel anomaly Using probiotics, antifungals, and/or antibiotics within the last three months Individuals with an autoimmune disease or weakened immune system Self-reported alcohol or drug use within the last 3 months Current use of over-the-counter medications, supplements, foods, and/or beverages that may affect stress, sleep, cognition, and/or mood Inability to swallow the study supplement due to swallowing anxiety Receiving treatment for a GI disease or condition diagnosed by a doctor other than constipation, gastroparesis, gastroesophageal reflux disease, or diverticular disease Positive results for human immunodeficiency virus (HIV) or Hepatitis B/C. Current history of active conditions of inflammatory bowel disease, irritable bowel syndrome, colitis, celiac disease, short bowel syndrome, colostomy, colectomy, gastrointestinal fistula, or strictures.
• Recent or current use of any antibiotic (within 4 weeks prior to the start of the study) Use of enemas or suppositories to relieve constipation Good adherence to the Mediterranean diet in the pre-start period according to the 14-item Mediterranean Diet Assessment Tool (score \>6)

Sponsors & Collaborators

• Medipol University: lead

Study Sites (1)

Medipol Mega Hospital

Istanbul, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Parkinson Disease; REM Sleep Behavior Disorder; Inflammation

Interventions

Dietary Supplements; Control Groups

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; REM Sleep Parasomnias; Parasomnias; Sleep Wake Disorders; Mental Disorders; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages; Epidemiologic Research Design; Epidemiologic Methods; Investigative Techniques; Research Design; Methods

Central Study Contacts

Rüken A Samancı

CONTACT

+90 543 939 15 94; rasamanci@medipol.edu.tr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Phd Candidate

Study Record Dates

• First Submitted: June 28, 2026
• First Posted: July 6, 2026
• Study Start: May 2, 2026
• Primary Completion (Estimated): September 25, 2026
• Study Completion (Estimated): October 20, 2026
• Last Updated: July 6, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)